Merus to Present at the 36th Annual J.P. Morgan Healthcare Conference
UTRECHT, The Netherlands, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D., Chief Executive Officer, will present a company overview at the 36th Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2018, at 9:30 a.m. PT.
A live webcast of the presentation will be available on the Investors page of the Company's website, http://www.merus.nl . An archived presentation will be available for 90 days.
About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics® . Biclonics® , which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have similar features as conventional monoclonal antibodies, such as long half-life and low immunogenicity. Merus' most advanced bispecific antibody candidate, MCLA-128, is expected to soon be evaluated in a Phase 2 combination trial in two metastatic breast cancer populations. MCLA-128 is also being evaluated in a Phase 1/2 clinical trial in Europe in gastric, ovarian, endometrial and non-small cell lung cancers. Merus' second most advanced bispecific antibody candidate, MCLA-117, is being developed in a Phase 1 clinical trial in patients with acute myeloid leukemia. The Company also has a pipeline of proprietary bispecific antibody candidates in preclinical development, including MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors, as well as MCLA-145, which is designed to bind to PD-L1 and a non-disclosed second immunomodulatory target and is being developed in collaboration with Incyte Corporation. For additional information, please visit Merus' website, www.merus.nl .
+1 646 368 8014
+1 973 361 1546
Information om Globenewswire
Følg pressemeddelelser fra Globenewswire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Globenewswire
Claroty21.5.2018 15:01 | pressemeddelelse
Claroty Launches Channel Program and Announces New Industrial Cybersecurity Partnerships
International Trademark Association21.5.2018 02:11 | pressemeddelelse
INTA Selects Singapore for 142nd Annual Meeting Slated for April 2020
GlobeNewswire, Inc.19.5.2018 07:01 | pressemeddelelse
GlobeNewswire Test Release
Talend17.5.2018 14:22 | pressemeddelelse
Talend Opens Nomination Period for Data Masters Awards
SEMAFO Inc.17.5.2018 13:02 | pressemeddelelse
SEMAFO: Boungou First Ore Expected in May and First Gold Pour in June
CellAegis Devices Inc.17.5.2018 13:02 | pressemeddelelse
CellAegis Announces Completion of Patient Enrollment in Danish Investigator Sponsored Clinical Trial Using autoRIC® Device
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum